Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma Previously Treated With Brentuximab or Checkpoint Inhibitors

NCT05039073 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT05039073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05039073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Brentuximab Vedotin Plus Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma Previously Treated With Brentuximab or Checkpoint Inhibitors
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Recruiting
Start date
May 2, 2022
Completion date
November 30, 2028
Enrollment
46 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent classic hodgkin lymphoma, refractory classic hodgkin lymphoma